SG Americas Securities LLC Trims Stock Position in iRhythm Technologies $IRTC

by · The Markets Daily

SG Americas Securities LLC decreased its position in iRhythm Technologies (NASDAQ:IRTC – Free Report) by 51.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,645 shares of the company’s stock after selling 14,344 shares during the period. SG Americas Securities LLC’s holdings in iRhythm Technologies were worth $2,347,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd acquired a new stake in iRhythm Technologies during the second quarter worth $39,000. Lazard Asset Management LLC acquired a new position in iRhythm Technologies in the second quarter valued at about $72,000. Strs Ohio purchased a new position in shares of iRhythm Technologies during the 1st quarter worth approximately $147,000. CWM LLC boosted its position in shares of iRhythm Technologies by 73.6% during the 3rd quarter. CWM LLC now owns 979 shares of the company’s stock worth $168,000 after purchasing an additional 415 shares during the period. Finally, State of Wyoming purchased a new stake in iRhythm Technologies in the second quarter valued at approximately $179,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IRTC shares. Citigroup increased their target price on iRhythm Technologies from $205.00 to $242.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Loop Capital set a $220.00 price objective on shares of iRhythm Technologies in a research note on Friday, October 31st. Canaccord Genuity Group upped their target price on shares of iRhythm Technologies from $193.00 to $212.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Robert W. Baird raised their price target on shares of iRhythm Technologies from $180.00 to $220.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. Finally, The Goldman Sachs Group boosted their price target on shares of iRhythm Technologies from $180.00 to $202.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $219.23.

Get Our Latest Report on iRhythm Technologies

iRhythm Technologies Trading Down 8.0%

NASDAQ IRTC opened at $155.44 on Wednesday. iRhythm Technologies has a 52 week low of $92.52 and a 52 week high of $212.00. The firm has a 50 day moving average of $176.47 and a two-hundred day moving average of $168.63. The company has a quick ratio of 4.50, a current ratio of 4.63 and a debt-to-equity ratio of 5.32. The stock has a market capitalization of $5.01 billion, a PE ratio of -96.55 and a beta of 1.12.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.30. The business had revenue of $192.88 million for the quarter, compared to analyst estimates of $184.75 million. iRhythm Technologies had a negative net margin of 7.32% and a negative return on equity of 41.86%. The company’s revenue was up 30.8% on a year-over-year basis. During the same period last year, the business earned ($1.26) EPS. As a group, research analysts expect that iRhythm Technologies will post -1.98 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Quentin S. Blackford sold 14,059 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $182.94, for a total transaction of $2,571,953.46. Following the completion of the sale, the chief executive officer owned 164,979 shares in the company, valued at $30,181,258.26. The trade was a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chad Patterson sold 280 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $51,752.40. Following the completion of the transaction, the insider directly owned 43,387 shares of the company’s stock, valued at $8,019,219.21. This trade represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 24,817 shares of company stock valued at $4,741,235 over the last quarter. Corporate insiders own 0.68% of the company’s stock.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

  • Positive Sentiment: Company-issued preliminary results and guidance: iRhythm said FY-2025 revenue will exceed prior guidance (~$740M) and expects FY-2026 revenue of $870–$880M (17%–18% growth) with an adjusted EBITDA margin of ~11.5%–12.5%; management highlighted record unit volume and first-time free cash flow positivity. GlobeNewswire release
  • Positive Sentiment: Analyst upgrades/price-target increases: Wells Fargo raised its price target to $225 and set an “overweight” rating, implying a sizable upside from current levels. Needham reaffirmed a buy and maintained a $244 target. These moves add institutional support to the upside case. Benzinga (Wells Fargo / Needham)
  • Neutral Sentiment: J.P. Morgan Healthcare Conference presentation: Management presented slides and a transcript (Q&A and strategic update). Useful for detail on expansion plans (primary care, AI risk stratification, adjacent markets) — may inform longer-term sentiment but not an immediate earnings release. Seeking Alpha slides Seeking Alpha transcript
  • Neutral Sentiment: Analyst coverage and price-target consensus remain strongly positive (multiple buy/overweight ratings, median target near $212), which supports a longer-term bull case but leaves the stock exposed to near-term volatility. Quiver Quant summary
  • Negative Sentiment: Insider selling: Quiver/GlobeNewswire data flagged extensive insider sales across several executives in recent months. Heavy insider selling can pressure sentiment and raise valuation/ timing concerns for some investors. Quiver Quant insider summary
  • Neutral Sentiment: Short-interest note appears unreliable: a reported “increase” to 0 shares with NaN changes and 0 days-to-cover is inconsistent and not actionable; treat this as non-informative until clarified by exchange data. (No direct link provided.)

iRhythm Technologies Profile

(Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

Featured Stories

Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRhythm Technologies (NASDAQ:IRTC – Free Report).